Immunomedics (IMMU) says results from a phase 2 trial suggest adding two ... Seeking Alpha Immunomedics (IMMU) says results from a phase 2 trial suggest adding two doses of epratuzumab may improve elderly large B-cell lymphoma patients' response to treatment with rituximab and CHOP chemotherapy. CEO Cynthia Sullivan calls the results ... |
